Search Results

Stereotactic spatial positioning and orientation of an instrument holder or tool guide to be used by a surgeon to manually guide standard neurosurgical instruments.

neuromate Gen III has been validated with the following stereotactic frames:

• 1 the Leksell Type G comprising of head frame and CT Localizer,
• 2 the CRW HRAIM with the BRWLF localizer.
• 3 the CRW UCHRA with the Luminant and BRWLF localizers

Not Found

This document is a 510(k) clearance letter for the neuromate Gen III device, a stereotaxic instrument. It confirms that the device is substantially equivalent to legally marketed predicate devices. However, this document does not contain any information about acceptance criteria or a study proving the device meets acceptance criteria.

The document primarily covers:

• The FDA's determination of substantial equivalence.
• Regulatory information regarding the device's classification, general controls, and compliance requirements.
• Instructions for reporting adverse events and seeking regulatory guidance.
• The device's Indications for Use, which describes its purpose (stereotactic spatial positioning and orientation of an instrument holder or tool guide for neurosurgical instruments) and the stereotactic frames it has been validated with.

Therefore, I cannot provide the requested information based on this document. The document confirms market clearance but does not detail the specific performance studies or acceptance criteria that led to that clearance.

Ask a specific question about this device

Stereotactic spatial positioning and orientation of an instrument holder or tool guide to be used by a surgeon to manually guide standard neurosurgical instruments.

neuromate Gen III has been validated with the Leksell Stereotactic System Type G (comprising of head frame and CT Localizer).

A stereotactic system with an electromechanical, multi jointed arm for spatial positioning and orientation of an instrument holder or tool-guide. Guidance is based on a preoperative plan developed with three-dimensional imaging software. The system is intended for use by neurosurgeons to guide standard neurosurgical instruments.

The provided text is a 510(k) Pre-market Notification for the neuromate Gen III device. It details the device's technical characteristics and compares it to a predicate device to establish substantial equivalence. However, the document does not include information about AI/ML models, multi-reader multi-case (MRMC) comparative effectiveness studies, or the types of clinical studies typically associated with proving the performance of AI-powered diagnostic devices.

The "study" referenced in the document is a performance validation of the mechanical accuracy of the stereotactic system, rather than an AI model.

Therefore, for your request, I will explain why many of the requested fields cannot be filled based on this document and address the parts that can be inferred.

This device (neuromate Gen III) is a stereotactic instrument, not an AI or imaging diagnostic device. The "validation" studies described relate to the mechanical accuracy and software performance of the medical device itself, not to the performance of an AI model in interpreting medical images or assisting human readers.

Acceptance Criteria and Device Performance (Based on "Performance Validation" of the Mechanical System)

The document describes "Performance Validation" of the neuromate Gen III system, focusing on its accuracy in the context of stereotactic surgery. This is about the mechanical accuracy of the robot.

Ask a specific question about this device

Stereotactic spatial positioning and orientation of an instrument holder or tool guide to be used by a surgeon to manually guide standard neurosurgical instruments.

A stereotactic system with an electromechanical, multi jointed arm for spatial positioning and orientation of an instrument holder or tool guide. Guidance is based on a preoperative plan developed with three-dimensional imaging software and utilizes ultrasonic registration. The system is intended for use by neurosurgeons to guide standard neurosurgical instruments.

This Renishaw Mayfield 510(k) summary does not contain information about acceptance criteria and a study demonstrating the device meets those criteria. Instead, it describes a device (Neuromate Frameless Gen II) as a technical update of a previously cleared predicate device (Frameless Neuromate). The submission focuses on demonstrating substantial equivalence to the predicate device, rather than proving performance against specific acceptance criteria with a dedicated study.

Specifically, the document states:

• No clinical data are submitted (Section 8). This indicates that there was no human-based study to assess the device's performance against clinical endpoints or acceptance criteria.
• Bench and performance testing showed that neuromate performed as designed and intended (Section 7). This refers to engineering-level testing to verify the device's functionality and compliance with standards (IEC 60601-1, IEC 60601-1-2, FDA software guidance, and IEC 62304), but it does not detail specific acceptance criteria or an associated study.
• The primary justification for market clearance is that the device "is equivalent in design and performance to the predicate device" (Section 9). The "Substantial Equivalence Summary" (Section 10) compares the new device to the predicate across various characteristics, noting similarities and minor differences.

Therefore, I cannot provide the requested information for acceptance criteria and a study proving the device meets them based on the provided text, as this type of information is not present in the document.

Ask a specific question about this device